Rosuvastatin 20 mg once daily bedtime. 2 month
Checking Date & Time
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Now I have all the information needed to provide a thorough analysis of this lipid report and the prescribed rosuvastatin therapy.
Lipid Profile Analysis — Mr. Zeher Ali Mondal (50 yr, Male)
Collected: 23 April 2026 | Lab: Dr Lal PathLabs
Current Lipid Values vs. Reference
| Parameter | Result | Reference | Status |
|---|---|---|---|
| Total Cholesterol | 264.22 mg/dL | <200 mg/dL | ❌ High |
| Triglycerides | 114.61 mg/dL | <150 mg/dL | ✅ Normal |
| HDL Cholesterol | 69.26 mg/dL | >40 mg/dL | ✅ Good |
| LDL Cholesterol | 172.04 mg/dL | <100 mg/dL | ❌ Markedly elevated |
| VLDL Cholesterol | 22.92 mg/dL | <30 mg/dL | ✅ Normal |
| Non-HDL Cholesterol | 195 mg/dL | <130 mg/dL | ❌ High |
Is Rosuvastatin 20 mg Appropriate?
Yes — this is a correct high-intensity statin choice.
Rosuvastatin 20 mg falls squarely in the high-intensity statin category, expected to lower LDL-C by ≥50% on average (Goldman-Cecil Medicine, Table 190-2). The ACC/AHA classification confirms:
| Intensity | Rosuvastatin dose | Expected LDL reduction |
|---|---|---|
| High | 20–40 mg | ≥50% |
| Moderate | 5–10 mg | 30–<50% |
What to Expect After 2 Months of Rosuvastatin 20 mg
With LDL currently at 172 mg/dL, a ≥50% reduction would bring it to approximately:
172 × 0.50 = ~86 mg/dL (best expected response) 172 × 0.65 = ~60 mg/dL (if high responder)
This is a pre-treatment baseline report. The next lipid panel should be checked after 4–12 weeks on therapy to assess response.
Treatment Goals — Which Risk Category Applies?
Without knowing if this patient has established ASCVD (prior MI, stroke, CAD), the goals differ:
| Clinical Situation | LDL-C Target (LAI 2023 / ADA) |
|---|---|
| No ASCVD, moderate risk | <100 mg/dL |
| High risk (multiple risk factors / DM) | <70 mg/dL |
| Very high risk (established ASCVD) | <50 mg/dL |
At 172 mg/dL, even achieving the moderate-risk target of <100 mg/dL requires a >41% reduction — well within what rosuvastatin 20 mg typically delivers.
What's Working in His Favour
- HDL is excellent at 69.26 mg/dL (>60 mg/dL is actually cardioprotective)
- Triglycerides are normal — no need for fenofibrate/omega-3 at this stage
- VLDL is normal
Action Points After 2 Months
- Repeat fasting lipid profile — check LDL response to rosuvastatin
- Check LFT and CK — baseline/follow-up for statin safety (hepatotoxicity, myopathy)
- If LDL ≥70 mg/dL after 2 months (and high-risk patient): add Ezetimibe 10 mg to further reduce by an additional ~20%
- If LDL target still not met on maximally tolerated statin + ezetimibe: consider PCSK9 inhibitor (evolocumab/alirocumab)
- Lifestyle modifications remain important regardless of drug therapy: reduce saturated fats, increase soluble fibre, regular aerobic exercise, avoid trans fats
Summary
Rosuvastatin 20 mg at bedtime is the correct drug at the correct dose (high-intensity statin per ACC/AHA / LAI 2023 guidelines). Given the baseline LDL of 172 mg/dL, a 50% reduction is expected to bring LDL to ~86 mg/dL — which would meet the <100 mg/dL moderate-risk goal. However, if this patient has established ASCVD or diabetes with multiple risk factors, a stricter target (<70 or <50 mg/dL) may require ezetimibe add-on therapy after reassessment.
Source: Goldman-Cecil Medicine, Table 190-2; Harrison's Principles of Internal Medicine 22E (2025); LAI Treatment Goals (as printed on the lab report)
⚠️ Disclaimer: This is educational information based on published guidelines. Clinical decisions should be made by the treating physician based on the full clinical picture including ASCVD risk status, comorbidities, and medication tolerance.
This is a shared conversation. Sign in to Orris to start your own chat.